34
total announcements
AARTIDRUGS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹3,644 Cr
P/E (TTM)
19.1
P/E (Forward)
14.3
EPS (TTM)
₹20.93
52W Low
₹318.95
52W High
₹534.00
Dividend Yield
0.50%
Beta
0.31
Price / Book
2.4
Debt / Equity
37.2
Revenue (TTM)
₹2,678 Cr
Gross Margin
37.52%
Operating Margin
11.46%
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the link of recording for the conference call regarding the financial results for the quarter ended June 30, 2026. The audio recording is available on the company's website.
Aarti Drugs Limited
Aarti Drugs Limited has published its standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Aarti Drugs Limited
Aarti Drugs Limited has released its Q1 FY27 investor presentation, highlighting a strong operational and financial performance driven by volume growth, improved realizations, and disciplined execution. The company reported a 19% YoY increase in net revenue from operations, with EBITDA and PBT margins expanding by 120bps and 120bps, respectively. The company's management commentary attributed the performance to a recovery in the pricing environment and operational efficiencies.
Aarti Drugs Limited
Aarti Drugs Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue standing at Rs. 703.6 crore, a 19% YoY growth, and EBITDA at Rs. 96.9 crore, a 30% YoY growth.
Aarti Drugs Limited
Aarti Drugs Limited has received a revocation order from the Gujarat Pollution Control Board (GPCB) regarding a closure direction issued for its plant located at Sayakha. The GPCB has accepted the company's application and has issued a revocation order, permitting the company to continue its operations. An interim Environmental Damage Compensation (EDC) of Rs. 10,20,000 has been levied as an interim measure.
Aarti Drugs Limited
Aarti Drugs Limited has announced leadership transition with Shri Rashesh C. Gogri elevated as Chairman and Managing Director, and Shri Adhish P. Patil appointed as Managing Director, effective October 1, 2026, replacing Shri Prakash M. Patil who will retire as Chairman, Managing Director & CEO.
Aarti Drugs Limited
Aarti Drugs Limited has announced the retirement of its Chairman, Managing Director, and CEO, Prakash M. Patil, effective September 30, 2026, and the appointment of Rashesh C. Gogri as the new Chairman, and Adhish P. Patil as the new Managing Director, both effective October 1, 2026. The company has also announced the re-appointment of several directors, including Harshit M. Savla, Harit P. Shah, Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi, for a further term of 5 years.
Aarti Drugs Limited
Aarti Drugs Limited has announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 5,085 lakhs and a revenue from operations of Rs. 70,278 lakhs.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of a conference call to discuss the company's financial performance for the quarter ended June 30, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has received a Closure Directions letter from the Gujarat Pollution Control Board (GPCB) under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974, mandating the closure of manufacturing operations at the Company’s plant located at Plot No. DP-94 to DP-96, Saykha Industrial Estate, Dist. Bharuch, Gujarat, effective 15 days from the date of issuance of the letter, alongside other related directions.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities and listing on stock exchanges.
Aarti Drugs Limited
Aarti Drugs Limited's promoter, Harshit M. Savla, has submitted a disclosure under SEBI Takeover Regulations, stating that two promoter group members, Mirik Rajendra Gogri and Renil Rajendra Gogri, have encumbered 6,41,814 and 5,97,957 shares respectively as of March 31, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has disclosed under SEBI Takeover Regulations that Shri Mirik Rajendra Gogri and Shri Renil Rajendra Gogri, Members of the Promoter Group, have encumbered 6,41,814 and 5,97,957 shares respectively as on March 31, 2026. No other encumbrance has been made by the Promoters/Promoter Group Members during the Financial Year ended March 31, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from July 1, 2026, until the expiry of 48 hours after the declaration of Financial Results for the Quarter ended June 30, 2026.